Elafibranor (ELA), a dual agonist of PPARα/δ, has been shown to ameliorate inflammation, steatosis, and fibrosis in animal models of NAFLD/NASH. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.